Mangoceuticals signs business combination deal with Nuclea Energy

Reuters2026/07/30 11:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mangoceuticals struck a business combination agreement with Nuclea Energy, an advanced nuclear developer focused on the lead-cooled Morpheus microreactor.
A newly formed Mangoceuticals subsidiary will merge with Nuclea, leaving Nuclea as an indirect wholly owned subsidiary of Mangoceuticals.
Nuclea shareholders will receive exchangeable shares, convertible one-for-one into Mangoceuticals common stock, with economics and votes designed to match.
Rights tied to the exchangeable shares will be capped at 19.99% of Mangoceuticals shares outstanding at closing until stockholder and Nasdaq approvals.
Morpheus is in conceptual design, targeted at 3.5 MWe to 50 MWe output, with an 18-month roadmap toward regulatory and commercial readiness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300700PRIMZONEFULLFEED9800729) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mangoceuticals signs business combination deal with Nuclea Energy

You may also like

Crypto prices